PLA2G4A and acute myeloid leukemia: In addition, we also identify PLA2G4A as a hub gene of signature and associated with prognosis and found that Nobiletin, a type of traditional Chinese medicine, targeting PLA2G4 may provide a third pathway for therapy AML.